Re:Search Institution Members
Choose one option to export the data.
Ahmadu Bello University, established in 1962, is a federal university in Zaria, Nigeria whose mission is to...
The Puerto Rico Science, Technology, and Research Institute invests, facilitates and builds capacity in order...
Usmanu Danfodiyo University, Sokoto (UDUS) was founded in 1975 as one of the initial twelve federal government...
The fellowship aims to improve the understanding of how naturally acquired immunity works to protect against clinical malaria. For that purpose, the host scientists Darren Creek and Christian Doerig at Monash University, Australia, and the fellow Abdirahman Abdi from the Kenya Medical Research Institute have conducted controlled human malaria infection on Kenyan adults who had had varying levels of prior exposure to natural malaria infection.
Rintis Noviyanti from the Eijkman Institute for Molecular Biology (EIMB), Indonesia, and the host scientists at the Walter and Eliza Hall of Medical Research (WEHI), Australia, Diana Hansen and Alan Cowman, employed advanced technology and research methods, including cytometry by time-of-flight (CyTOF), and fluorescence-activated cell sorting (FACS), a derivative of flow cytometry that adds an exceptional degree of functionality for sorting cells. They used these technologies and methods, together with data mining and analysis, to identify biological markers present in individuals with natural immunity to Malaria.
This fellowship of Indra Wibowo from the Institut Teknologi Bandung, Indonesia, with Wai-Hong Tham from the Walter and Eliza Hall Institute of Medical Research (WEHI), Australia, aimed to identify functional blocking antibodies that inhibit red blood cell binding and ligand-receptor interactions present in individuals in a region of high Malaria transmission in Indonesia. PfRh5 is one of the leading vaccine candidates against blood stage P. falciparum and PfRh4 governs the major invasion pathway independent of glycophorin-mediated entry.
Institute Pasteur Madagascar (IPM) is working with cohorts of EPTB (Extrapulmonary tuberculosis) patients in collaboration with local clinicians to better diagnose EPTB and accelerate diagnosis. IPM is gathering clinical, bacteriological as well immunological data and samples from these patients (clinical extrapulamonary Mtb (mycobacterium tuberculosis) strains, blood samples and other fluids), aiming to increase the Institute immunological investigation capacities in order to propose new options with new tools to diagnose EPTB with an integrated approach (host, pathogen, immune response). At IPM, the human host capacities need to be upgraded to meet with the international standards and increase the capacity to understand the host-pathogen interaction and build tools to fight against EPTB from this interaction. In this project, Paulo Ranaivomanana from IPM and Anna Coussens from WEHI have worked together to strengthen IPM capacities in assessing the immunological correlates that may be associated with extrapulmonary dissemination of Mtb. Understanding the determinants of Mtb dissemination can be useful to build diagnostic tools for EPTB.
It is estimated that one quarter of the world’s population is infected with tuberculosis (TB). To deter the growing threat of multidrug-resistant tuberculosis, new treatments are needed to successfully reduce the global burden of this disease. Dr. Cynthia Dowd from The George Washington University (GW) has developed lead compounds with anti-tubercular activity, wich could be promising candidates for TB drug development. In order to assist Dr. Dowd in target identification, MSD will be screening these compounds to determine their activity against a specific Mycobacterium tuberculosis target.
Professor Fabrice Boyom, head of the Antimicrobial & Biocontrol Agents Unit (AmBcAU) at the University of Yaounde I, is working toward the discovery and development of novel drugs against HAT, Leishmaniasis, and Malaria by targeting the parasites’ critical metabolic pathways. To support Professor Boyom’s drug discovery efforts, Eisai will share dihydrofolate reductase (DHFR) inhibitors and potassium channel blockers.